Posts in ATSP-7041
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.

Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM. Cancer Res. 2019 ;79(9):2404-2414

http://cancerres.aacrjournals.org/content/79/9/2404.long

Read More
ATSP-7041Liz Tompkins
Design, Synthesis, Biophysical and Structure-Activity Properties of a Novel Dual MDM2 and MDMX Targeting Stapled α-Helical Peptide: ATSP-7041 Exhibits Potent In Vitro and In Vivo Efficacy in...

V. Guerlavais, K. Darlak, B. Graves, C. Tovar, K. Packman, K. Olson, K. Kesavan, P. Gangurde, J. Horstick, A. Mukherjee, T. Baker, X.E. Shi, S. Lentini, K. Sun, S. Irwin, E. Feyfant, T. To, Z. Filipovic, C. Elkin, J. Pero, S. Santiago, T. Bruton, T. Sawyer, A. Annis, N. Fotouhi, T. Manning, H. Nash, L.T. Vassilev, Y.S. Chang and T.K. Sawyer. Proceedings of the 23rd American Peptide symposium, American Peptide Society, 2013, 217-218

https://www.americanpeptidesociety.org/assets/pdf-files/proceedings/23.pdf

Read More
ATSP-7041Liz Tompkins
Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Chang

Chang, Y.S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K. -H., Olson, K. A., Kesavan, K., Gangurde, P., Mukherjee, A., Baker, T., Darlak, K., Elkin, C., Filipovic, Z., Qureshi, F. Z., Cai, H., Berry, P., Feyfant, E., Shi, X. E., Horstick, J., Annis, D. A., Manning, A. M., Fotouhi, N., Nash, H., Vassilev, L. T. & Sawyer, T. K. Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA. 2013; 110(36):E3445-54.

http://www.pnas.org/content/early/2013/08/13/1303002110.full.pdf

Read More
ATSP-7041Liz Tompkins